Y-mAbs Therapeutics (YMAB) Tops Q2 EPS by 11c

Y-mAbs Therapeutics (NASDAQ: YMAB) reported Q2 EPS of ($0.53), $0.11 better than the analyst estimate of ($0.64). Revenue for the quarter came in at $8.95 million versus the consensus estimate of $7.85 million.

“We are very pleased with our second quarter 2021 results. The commercialization of DANYELZA® (naxitamab-gqgk) is progressing throughout the U.S. as we continue to see new sites gaining experience with DANYELZA. In addition, the DANYELZA BLA submission has recently been accepted by the National Medical Products Administration of China (“NMPA”), and we continue to advance our deep pipeline. We ended the quarter with a cash balance of $233.6 million, so we believe we are well positioned to elevate our business to new levels,” stated Thomas Gad, founder, Chairman and President.

Dr. Claus Moller, Chief Executive Officer, continued, “We submitted the European Marketing Authorization Application to the European Medicines Agency (the “EMA”) for omburtamab in April. In parallel, after our Type B meeting with the FDA in June, we believe we now have a clearer path towards the resubmission of the omburtamab BLA to the FDA. Pending a positive Type B meeting with the FDA in the third quarter, we hope to initiate rolling resubmission of the omburtamab BLA by the end of the year.”

For earnings history and earnings-related data on Y-mAbs Therapeutics (YMAB) click here.

You May Also Be Interested In

• BayCom Corp (BCML) Misses Q1 EPS by 4c
• P.A.M. Transportation Services (PTSI) Misses Q1 EPS by 9c
• PPG Industries (PPG) Reports In-Line Q1 EPS, offers outlook